Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029

1.1 List of Tables
1.2 List of Figures

2.1 IPF Market to Experience Conservative Growth over the Forecast Period
2.2 Innovative Small Pharma Require Partnerships to Sustain Development
2.3 High Unmet Clinical Needs Remain
2.4 Late-Stage Pipeline Fractured Among Many Differing Mechanisms of Action
2.5 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.2.1 GAP Model
4.2.2 Stratification by Decline in Forced Vital Capacity (FVC)

5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for IPF (2019-2029)
5.5.1 Diagnosed Incident Cases of IPF
5.5.2 Sex-Specific Diagnosed Incident Cases of IPF
5.5.3 Age-Specific Diagnosed Incident Cases of IPF
5.5.4 Diagnosed Prevalent Cases of IPF
5.5.5 Sex-Specific Diagnosed Prevalent Cases of IPF
5.5.6 Age-Specific Diagnosed Prevalent Cases of IPF
5.5.7 Diagnosed Prevalent Cases of IPF by Severity
5.5.8 Diagnosed Prevalent Cases of IPF by Comorbidities
5.5.9 Total Prevalent Cases of IPF
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Coronavirus Disease 2019 (COVID-19) Impact
5.6.3 Limitations of Analysis
5.6.4 Strengths of Analysis

6.1 Overview
6.2 Current Treatment Guidelines
6.3 Symptomatic Treatments

7.1 Overview
7.2 Earlier Diagnosis
7.3 Improved Drug Safety and Efficacy
7.4 Improvement in Patient Quality of Life
7.5 Treatments for Patients with Severe Disease

8.1 Overview
8.1.1 Corporate Partnerships
8.1.2 Combination Therapy
8.2 Clinical Trial Design
8.2.1 Appropriate Endpoints
8.2.2 Increased Use of Quality of Life Measures
8.2.3 Add-Ons to Standard of Care
8.2.4 Selection of Patient Population

9.1 Overview
9.2 Continuity of Care
9.3 Trial Logistics
9.3.1 Recruitment
9.3.2 Trial Conduct in Isolation
9.3.3 Supply Chain
9.4 Long-Term Impact on the Disease Space

10.1 Overview
10.2 Innovative Early-Stage Approaches

11.1 Clinical Benchmark of Key Pipeline Drugs
11.2 Commercial Benchmark of Key Pipeline Drugs
11.3 Competitive Assessment
11.4 Top-Line 10-Year Forecast
11.4.1 US
11.4.2 5EU
11.4.3 Japan

Table 1: IPF: Key Metrics in the 7MM
Table 2: The GAP Index
Table 3: Risk Factors and Comorbidities for IPF
Table 4: Diagnosed Prevalent Cases of IPF by Comorbidities, N, Both Sexes, Ages =18 Years, 2019
Table 5: Treatment Guidelines for IPF, 2020
Table 6: Leading Treatments for IPF, 2020
Table 7: Early Stage Pipeline Agents for IPF, 2020
Table 8: Clinical Benchmark of Key Pipeline Drugs - IPF
Table 9: Commercial Benchmark of Key Pipeline Drugs - IPF
Table 10: IPF Market - Global Drivers and Barriers, 2019-2029
Table 11: Key Events Impacting US Sales for IPF, 2019-2029
Table 12: Key Events Impacting 5EU Sales for IPF, 2019-2029
Table 13: Key Events Impacting Japan Sales for IPF, 2019-2029
Table 14: Key Historical and Projected Launch Dates for IPF
Table 15: Key Historical and Projected Patent Expiry Dates for IPF
Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for IPF in 2019 and 2029
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC), Esbriet and Ofev
Figure 3: The Induction and Progression of IPF
Figure 4: 7MM, Diagnosed Incidence of IPF (Cases per 100,000 Population), Both Sexes, Ages =18 Years, 2019
Figure 5: 7MM, Diagnosed Prevalence of IPF, Both Sexes, Ages =18 Years, 2019
Figure 6: 7MM, Total Prevalence of IPF, Both Sexes, Ages =18 Years, 2019
Figure 7: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of IPF
Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Severity
Figure 9: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of IPF by Comorbidities
Figure 10: 7MM, Diagnosed Incident Cases of IPF, N, Both Sexes, Ages =18 Years, 2019
Figure 11: 7MM, Diagnosed Incident Cases of IPF, N, by Sex, Ages =18 Years, 2019
Figure 12: 7MM, Diagnosed Incident Cases of IPF by Age, N, Both Sexes, 2019
Figure 13: 7MM, Diagnosed Prevalent Cases of IPF, N, Both Sexes, Ages =18 Years, 2019
Figure 14: 7MM, Diagnosed Prevalent Cases of IPF, N, by Sex, Ages =18 Years, 2019
Figure 15: 7MM, Diagnosed Prevalent Cases of IPF by Age, N, Both Sexes, 2019
Figure 16: 7MM, Diagnosed Prevalent Cases of IPF by Severity, N, Both Sexes, Ages =18 Years, 2019
Figure 17: 7MM, Total Prevalent Cases of IPF, N, Both Sexes, Ages =18 Years, 2019
Figure 18: Unmet Needs and Opportunities in IPF
Figure 19: Overview of the Development Pipeline in IPF
Figure 20: Key Phase II/III Trials for Therapeutic Agents that Target IPF Disease Progression
Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the Standard of Care (SOC)
Figure 22: Global (7MM) Sales Forecast by Country for IPF in 2019 and 2029
Figure 23: Global Sales Forecast by Molecule for IPF in 2019 and 2029
Figure 24: Sales Forecast by Class for IPF in the US in 2019 and 2029
Figure 25: Sales Forecast by Class for IPF in the 5EU in 2019 and 2029
Figure 26: Sales Forecast by Class for IPF in Japan in 2019 and 2029